Nona Biosciences and Candid Therapeutics Collaborate on Innovative T-Cell Engagers

Collaboration Announcement between Nona Biosciences and Candid Therapeutics



Nona Biosciences, a leading global biotechnology firm known for its comprehensive solutions from "Idea to IND" (Investigational New Drug), has recently forged a significant research collaboration with Candid Therapeutics, Inc. This agreement aims to accelerate the development of next-generation T-cell engagers (TCEs), specifically designed to address autoimmune diseases.

This groundbreaking partnership underscores both companies' commitment to innovating therapeutic approaches in the field of immunology. Candid, a clinical-stage biotechnology entity located in San Diego, has positioned itself as a frontrunner in TCE advancements aimed at B-cell depletion and the treatment of autoimmune disorders. Under the terms of the collaboration, Nona Biosciences is poised to receive up to $320 million—a figure that includes an initial payment along with a series of milestone payouts as the project progresses.

Dr. Jingsong Wang, the Chairman of Nona Biosciences, expressed enthusiasm for the alliance, highlighting their proprietary HBICE® technology platform. He noted the distinct advantages of their T-cell engagers such as precise targeting capabilities, adaptative formats, improved efficacy, and heightened safety profiles. Dr. Wang stated, "Leveraging our industry-leading technology, along with our profound expertise in antibody development, we are eager to assist Candid in advancing revolutionary treatments that offer newfound hope to patients suffering from autoimmune conditions."

On the side of Candid Therapeutics, Chief Executive Officer Dr. Ken Song echoed the sentiment, remarking on Nona’s impressive capabilities in discovery and research. "We anticipate this collaboration will yield innovative T-cell engagers that can make a meaningful impact on patient lives," he said.

About Nona Biosciences



Nona Biosciences is at the forefront of biotechnology, delivering innovative technologies and comprehensive services tailored to support research projects from inception to clinical trial readiness. Their suite of antibody and related discovery services encompasses advanced modalities such as antigen preparation, animal immunization, single B cell screening, and antibody lead generation. The firm’s proprietary Harbour Mice® platform facilitates the generation of fully human monoclonal antibodies in diverse formats.

With the integration of the Harbour Mice technology and other leading-edge methods, Nona Biosciences is dedicated to spearheading global innovations in the development of transformative next-generation medications. For more information, explore their offerings online at www.nonabio.com.

About Candid Therapeutics, Inc.



Candid Therapeutics is a clinical-stage biotechnology firm founded in 2024, dedicated to pioneering T-cell engagers aimed at depleting B-cells for the treatment of autoimmune diseases. The company is advancing two primary TCE antibody drug candidates that target various B-cell protein signatures, exploring the breadth of T-cell engagement across a spectrum of autoimmune disorders. Candid’s capable leadership team has a proven track record in advancing therapeutic programs through all stages of development. For more information, visit Candid Therapeutics

Through this collaboration, Nona Biosciences and Candid Therapeutics are set to redefine therapeutic paradigms in autoimmune disease management, potentially ushering in a new era of targeted therapies that promote effective and safe treatment protocols. Their commitment to innovation not only emphasizes the importance of collaboration in the scientific community but also highlights the potential to change the lives of patients worldwide.

Topics Health)

【About Using Articles】

You can freely use the title and article content by linking to the page where the article is posted.
※ Images cannot be used.

【About Links】

Links are free to use.